Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018044858) C5 IMMUNIZATION FOR AUTOLOGOUS ANTI-C5 ANTIBODY PRODUCTION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/044858 International Application No.: PCT/US2017/049059
Publication Date: 08.03.2018 International Filing Date: 29.08.2017
IPC:
A61K 38/16 (2006.01) ,A61K 38/17 (2006.01) ,A61K 39/12 (2006.01) ,A61K 39/39 (2006.01) ,A61K 39/395 (2006.01) ,C07K 7/06 (2006.01) ,C07K 7/08 (2006.01) ,C07K 16/08 (2006.01) ,C12N 5/10 (2006.01)
[IPC code unknown for A61K 38/16][IPC code unknown for A61K 38/17][IPC code unknown for A61K 39/12][IPC code unknown for A61K 39/39][IPC code unknown for A61K 39/395][IPC code unknown for C07K 7/06][IPC code unknown for C07K 7/08][IPC code unknown for C07K 16/08][IPC code unknown for C12N 5/10]
Applicants:
THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Avenue Cleveland, Ohio 44195, US
GEORGIA TECH RESEARCH CORPORATION [US/US]; 505 Tenth Street NW Atlanta, Georgia 30332, US
Inventors:
LIN, Feng; US
FINN, M.G.; US
Agent:
BOND, Jason, R.; US
Priority Data:
62/380,82429.08.2016US
Title (EN) C5 IMMUNIZATION FOR AUTOLOGOUS ANTI-C5 ANTIBODY PRODUCTION
(FR) IMMUNISATION À L'AIDE D'ÉPITOPES C5 POUR LA PRODUCTION D'ANTICORPS ANTI-C5 AUTOLOGUES
Abstract:
(EN) Provided herein are immunogenic compositions comprising an immunogen with at least one complement component 5 (C5) epitope, wherein the immunogen is capable of generating autologous anti-C5 antibodies in a subject. In certain embodiments, such compositions are employed for treating and preventing complement component 5 (C5) related diseases. In certain embodiments, the immunogenic compositions comprise virus like particles and/or PADRE sequences, in addition to the C5 epitope(s).
(FR) L'invention concerne des compositions immunogènes comprenant un immunogène comportant au moins un épitope du composant 5 (C5) du complément, l'immunogène étant capable de générer des anticorps anti-C5 autologues chez un sujet. Dans certains modes de réalisation, de telles compositions sont utilisées pour traiter et prévenir les maladies associées au composant 5 (C5) du complément. Dans certains modes de réalisation, les compositions immunogènes comprennent des pseudo-particules virales et/ou des séquences PADRE, en plus du ou des épitopes C5.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)